HALTRUST 440 INJECTION

Content Reviewed By:

Written By:

• HALTRUST 440 INJECTION is a targeted therapy designed to combat cancers that overexpress the HER2 protein. The HER2 protein, or human epidermal growth factor receptor 2, is a protein found on the surface of cells. In some cancers, HER2 is present in excessive amounts, leading to uncontrolled cell growth and division. HALTRUST 440 INJECTION works by selectively binding to the HER2 protein on cancer cells. This binding action has several important effects.
• First, it directly inhibits the HER2 signaling pathway, which is responsible for stimulating cancer cell growth. By blocking this pathway, HALTRUST 440 INJECTION helps to slow down or stop the proliferation of cancer cells. Second, it can mark cancer cells for destruction by the body's immune system. This antibody-dependent cell-mediated cytotoxicity (ADCC) helps the immune system recognize and eliminate cancer cells that express HER2.
• Furthermore, HALTRUST 440 INJECTION can also prevent the cancer cells from shedding the HER2 protein, making it more accessible to the drug's targeting mechanism and maintaining the drug's effectiveness for a longer period. This targeted approach minimizes damage to healthy cells, reducing the side effects often associated with traditional chemotherapy. HALTRUST 440 INJECTION is a vital component in the treatment of HER2-positive cancers, offering a more precise and effective way to combat the disease.

• HALTRUST 440 INJECTION is typically administered either before or after a surgical procedure, depending on your specific medical needs and the judgment of your healthcare provider. This medication is given intravenously, meaning it's delivered directly into your vein through a small needle or catheter.
• The initial infusion of HALTRUST 440 INJECTION usually takes around 90 minutes. During this time, your medical team will closely monitor you for any signs of adverse reactions or intolerance to the medication. If the first infusion is well-tolerated and you experience no significant side effects, subsequent doses may be administered more quickly, typically over a 30-minute period.
• It's crucial to follow your doctor's instructions precisely regarding the administration of HALTRUST 440 INJECTION. Do not attempt to self-administer the medication. The dosage and timing will be determined by your doctor based on factors such as your weight, kidney function, and the specific condition being treated. Always inform your doctor or nurse immediately if you experience any discomfort or unusual symptoms during the infusion.